Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis.

To summarize and clarify the association between vascular endothelial growth factor () and vascular endothelial growth factor receptor () polymorphisms and the outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. A total of 8 studies including 900 patients were analyzed in this systematic review after screening the database of PubMed, EMBASE and Web of Science. Hazard ratios (HRs) with 95% confidence interval (CI) were used to evaluate the strength of the association. VEGFR1 rs9582036 AA/AC carriers and rs9554320 CC/AC carriers had more favorable overall survival (OS) in patients with mRCC treated with sunitinib ( = 3), but not in progression-free survival (PFS). In addition, rs2010963 was associated with poorer PFS of mRCC ( = 1). rs699947 was significant in predicting PFS by univariate analysis, but showed no statistical significance in OS ( = 1). rs1870377 was verified to be associated with sunitinib OS ( = 1). Furthermore, patients with rs307826 and rs307821 had shorter PFS and OS during sunitinib therapy ( = 2, respectively). Our results suggested that and polymorphisms were associated with outcomes in sunitinib treated mRCC patients, especially polymorphisms. However, considering the limited study numbers, its clinical application in sunitinib treated mRCC still needs further confirmation.